300725 药石科技
已收盘 06-03 15:00:00
资讯
新帖
简况
药石科技：公司主营业务为提供从药物发现到商业化生产的全面一体化CRDMO服务
证券之星 · 06-03 17:00
药石科技：公司主营业务为提供从药物发现到商业化生产的全面一体化CRDMO服务
药石科技：截至2026年第一季度末，公司在手订单金额同比增长超过20%
证券之星 · 06-03 17:00
药石科技：截至2026年第一季度末，公司在手订单金额同比增长超过20%
药石科技：南京药石“新分子药物研发平台项目”首期预计于2026年第三季度投入使用
证券之星 · 05-25
药石科技：南京药石“新分子药物研发平台项目”首期预计于2026年第三季度投入使用
股市必读：药石科技（300725）5月22日董秘有最新回复
证券之星 · 05-25
股市必读：药石科技（300725）5月22日董秘有最新回复
药石科技：仲丁基锂连续流工艺成功应用
证券之星 · 05-23
药石科技：仲丁基锂连续流工艺成功应用
5月14日药石科技跌5.59%，信澳优享生活混合A基金重仓该股
证券之星 · 05-14
5月14日药石科技跌5.59%，信澳优享生活混合A基金重仓该股
药石科技：公司在高活性试剂连续流工艺等领域的技术积累
证券之星 · 05-07
药石科技：公司在高活性试剂连续流工艺等领域的技术积累
股市必读：药石科技（300725）5月6日披露最新机构调研信息
证券之星 · 05-07
股市必读：药石科技（300725）5月6日披露最新机构调研信息
4月28日药石科技涨5.11%，信澳优享生活混合A基金重仓该股
证券之星 · 04-28
4月28日药石科技涨5.11%，信澳优享生活混合A基金重仓该股
股市必读：药石科技（300725）4月24日董秘有最新回复
证券之星 · 04-27
股市必读：药石科技（300725）4月24日董秘有最新回复
药石科技：截至2026年4月20日，公司股东人数42,718名
证券之星 · 04-24
药石科技：截至2026年4月20日，公司股东人数42,718名
药石科技(300725)3月31日股东户数4.33万户，较上期增加0.97%
证券之星 · 04-22
药石科技(300725)3月31日股东户数4.33万户，较上期增加0.97%
药石科技(300725.SZ)发布一季度业绩，归母净利润4888.66万元，增长36.59%
智通财经 · 04-21
药石科技(300725.SZ)发布一季度业绩，归母净利润4888.66万元，增长36.59%
药石科技：截至2026年3月31日，公司股东人数43,282名
证券之星 · 04-12
药石科技：截至2026年3月31日，公司股东人数43,282名
药石科技：浙江晖石生产基地多肽GMP中试车间项目目前已完成主体建设
证券之星 · 04-12
药石科技：浙江晖石生产基地多肽GMP中试车间项目目前已完成主体建设
泓博医药：公司与药石科技未开展相关合作
证券日报网 · 04-03
泓博医药：公司与药石科技未开展相关合作
诺思格：药石科技为创新药提供临床前服务，我公司为临床CRO公司
证券之星 · 04-03
诺思格：药石科技为创新药提供临床前服务，我公司为临床CRO公司
昂利康：目前公司与药石科技暂无合作事项
证券之星 · 04-02
昂利康：目前公司与药石科技暂无合作事项
重药控股：目前公司没有与药石科技合作
证券之星 · 04-02
重药控股：目前公司没有与药石科技合作
4月1日药石科技涨5.63%，方正富邦新兴成长混合A基金重仓该股
证券之星 · 04-01
4月1日药石科技涨5.63%，方正富邦新兴成长混合A基金重仓该股
加载更多
公司概况
公司名称：
南京药石科技股份有限公司
所属行业：
化学原料和化学制品制造业
上市日期：
2017-11-10
主营业务：
南京药石科技股份有限公司的主营业务是为小分子药物研发领域提供创新型化学产品和相关技术服务。公司的主要产品是药物研究阶段的产品和服务、药物开发及商业化阶段的产品和服务。公司在标普全球企业可持续发展评估（S＆PCSA）中得分58分，位列行业前列，入选《可持续发展年鉴（中国版）2026》并荣获“制药行业最佳进步企业”称号；在CDP（全球环境信息研究中心）气候变化与水安全问卷评级中均获得B级。此外，公司再度荣获WindESGAA评级，总分在CRDMO行业中位居前列，其中环境维度获得满分。
发行价格：
11.32
{"stockData":{"symbol":"300725","market":"SZ","secType":"STK","nameCN":"药石科技","latestPrice":34.5,"timestamp":1780470234000,"preClose":34.31,"halted":0,"volume":5661334,"delay":0,"changeRate":0.0055,"floatShares":202999999,"shares":234000000,"eps":0.8419,"marketStatus":"已收盘","change":0.19,"latestTime":"06-03 15:00:00","open":34.36,"high":35.3,"low":33.98,"amount":197000000,"amplitude":0.0385,"askPrice":34.52,"askSize":1,"bidPrice":34.5,"bidSize":62,"shortable":0,"etf":0,"ttmEps":0.8419,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780536600000},"marketStatusCode":5,"adr":0,"adjPreClose":34.31,"symbolType":"stock","openAndCloseTimeList":[[1780450200000,1780457400000],[1780462800000,1780470000000]],"highLimit":37.74,"lowLimit":30.88,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":233807341,"isCdr":false,"pbRate":1.46,"roa":"--","peRate":40.978739,"roe":"0.83%","epsLYR":0.88,"committee":0.28382,"marketValue":8066000000,"turnoverRate":0.0279,"status":0,"floatMarketCap":6994000000},"requestUrl":"/m/hq/s/300725/","defaultTab":"news","newsList":[{"id":"2640970840","title":"药石科技：公司主营业务为提供从药物发现到商业化生产的全面一体化CRDMO服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2640970840","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640970840?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:00","pubTimestamp":1780477248,"startTime":"0","endTime":"0","summary":"国内创新药研发扩容能否完全对冲美国客户的政策风险？公司始终密切关注全球医药行业政策与监管环境的变化，并基于对行业趋势的研判，持续完善自身的风险管理体系。公司主营业务为提供从药物发现到商业化生产的全面一体化CRDMO服务，核心优势在于绿色与智能化学技术平台。目前，公司生产经营一切正常，具体业务与财务数据请以公司在巨潮资讯网披露的定期报告及公告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300034164.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300725","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640697087","title":"药石科技：截至2026年第一季度末，公司在手订单金额同比增长超过20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640697087","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640697087?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:00","pubTimestamp":1780477247,"startTime":"0","endTime":"0","summary":"证券之星消息，药石科技06月03日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，2025年公司北美（美国）客户收入占比约46.8%，请问其中受美国BIOSECURE法案、Harris修正案潜在影响的订单占比多少？美国客户是否出现订单下滑、转移欧洲/亚洲产能的情况？目前，公司各项业务进展顺利。截至2026年第一季度末，公司在手订单金额同比增长超过20%，生产经营一切正常。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300034163.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300725","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638539100","title":"药石科技：南京药石“新分子药物研发平台项目”首期预计于2026年第三季度投入使用","url":"https://stock-news.laohu8.com/highlight/detail?id=2638539100","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638539100?lang=zh_cn&edition=full","pubTime":"2026-05-25 17:18","pubTimestamp":1779700689,"startTime":"0","endTime":"0","summary":"经公司2026年第一次临时股东会审议批准，原募投项目浙江晖石“年产 155 吨创新药及关键中间体 CDMO 建设项目”已变更为南京药石 “新分子药物研发平台项目”与浙江晖石“化学合成新分子药物建设项目”。目前，两个新项目均按计划有序推进：南京药石 “新分子药物研发平台项目”首期预计于2026 年第三季度投入使用；浙江晖石“化学合成新分子药物建设项目”中的多肽中试车间预计于2026 年第二季度投入使用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500024007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","300725"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638330734","title":"股市必读：药石科技（300725）5月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2638330734","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638330734?lang=zh_cn&edition=full","pubTime":"2026-05-25 03:49","pubTimestamp":1779652149,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，药石科技报收于37.64元，上涨0.03%，换手率3.63%，成交量7.35万手，成交额2.76亿元。公司将持续关注客户需求，支持该项目的后续生产与供应。公司的法定信息披露渠道为巨潮资讯网及指定媒体，公司具体的经营数据、未来的业务拓展计划请关注公司发布的相关公告。当日关注点来自交易信息汇总：5月22日主力资金净流出269.25万元，游资资金净流入566.6万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500001575.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","300725"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637219322","title":"药石科技：仲丁基锂连续流工艺成功应用","url":"https://stock-news.laohu8.com/highlight/detail?id=2637219322","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637219322?lang=zh_cn&edition=full","pubTime":"2026-05-23 20:39","pubTimestamp":1779539948,"startTime":"0","endTime":"0","summary":"证券之星消息，药石科技05月23日在投资者关系平台上答复投资者关心的问题。针对您集中提出的仲丁基锂连续流应用的多个问题，公司现统一回复如下：仲丁基锂连续流工艺的成功应用，旨在解决医药合成中高活性试剂的安全与规模化生产难题，目前主要服务于公司医药研发与生产业务的需求，以提升相关反应的安全性、效率与绿色化水平。以上内容为证券之星据公开信息整理，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052300014287.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","300725"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635792738","title":"5月14日药石科技跌5.59%，信澳优享生活混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2635792738","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635792738?lang=zh_cn&edition=full","pubTime":"2026-05-14 16:40","pubTimestamp":1778748052,"startTime":"0","endTime":"0","summary":"证券之星消息，5月14日药石科技跌5.59%，收盘报37.68元，换手率5.59%，成交量11.33万手，成交额4.39亿元。融资融券方面近5日融资净流出1253.1万，融资余额减少；融券净流入1950.0，融券余额增加。重仓药石科技的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为信达澳亚基金的信澳优享生活混合A。该公募基金现任基金经理为杨珂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400028835.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1500","01717","300725","BK0229","BK1553","BK1597","BK1237"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633113694","title":"药石科技：公司在高活性试剂连续流工艺等领域的技术积累","url":"https://stock-news.laohu8.com/highlight/detail?id=2633113694","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633113694?lang=zh_cn&edition=full","pubTime":"2026-05-07 15:48","pubTimestamp":1778140098,"startTime":"0","endTime":"0","summary":"证券之星消息，药石科技05月07日在投资者关系平台上答复投资者关心的问题。公司在高活性试剂连续流工艺等领域的技术积累，目前主要服务于医药研发与生产的需求，旨在提升反应的安全性、效率与绿色化水平。公司始终关注包括连续流、催化等在内的绿色化学技术的发展与应用前景，并将基于自身战略规划与核心能力，审慎评估相关技术的延伸可能性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700021366.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","300725"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633623153","title":"股市必读：药石科技（300725）5月6日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2633623153","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633623153?lang=zh_cn&edition=full","pubTime":"2026-05-07 01:52","pubTimestamp":1778089931,"startTime":"0","endTime":"0","summary":"截至2026年5月6日收盘，药石科技报收于40.09元，上涨0.6%，换手率4.78%，成交量9.69万手，成交额3.88亿元。当日关注点来自交易信息汇总：5月6日主力资金净流出878.96万元，游资资金净流入1468.19万元。来自机构调研要点：南京学府路场地升级改造项目预计2026年第二季度投入使用，多个研发及中试项目将陆续投产。2025年第四季度营收同比微降0.95%，主因2024年同期特定订单集中交付；综合毛利率为30.48%，与年内其他季度基本持平。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700001270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300725","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630689376","title":"4月28日药石科技涨5.11%，信澳优享生活混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2630689376","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630689376?lang=zh_cn&edition=full","pubTime":"2026-04-28 16:34","pubTimestamp":1777365261,"startTime":"0","endTime":"0","summary":"证券之星消息，4月28日药石科技涨5.11%，收盘报40.7元，换手率9.08%，成交量18.41万手，成交额7.41亿元。重仓药石科技的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为信达澳亚基金的信澳优享生活混合A。该公募基金现任基金经理为杨珂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800049305.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1237","300725","BK1553","BK1597","BK1500","01717","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630350623","title":"股市必读：药石科技（300725）4月24日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2630350623","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630350623?lang=zh_cn&edition=full","pubTime":"2026-04-27 02:47","pubTimestamp":1777229229,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，药石科技报收于38.17元，下跌0.75%，换手率3.64%，成交量7.37万手，成交额2.82亿元。董秘最新回复投资者： 尊敬的董秘您好，麻烦告知公司截至最新日期的股东总户数，感谢回复。董秘： 截至2026年4月20日，公司股东人数42,718名。董秘： 投资者您好，2026 年第一季度公司在手订单增长超过 20%，为全年业绩奠定了良好基础。当日关注点来源：交易信息汇总：4月24日主力资金净流出2204.16万元，显示主力短期看空情绪明显。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700005195.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","300725"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629103618","title":"药石科技：截至2026年4月20日，公司股东人数42,718名","url":"https://stock-news.laohu8.com/highlight/detail?id=2629103618","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629103618?lang=zh_cn&edition=full","pubTime":"2026-04-24 18:21","pubTimestamp":1777026066,"startTime":"0","endTime":"0","summary":"证券之星消息，药石科技(300725)04月24日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好，麻烦告知公司截至最新日期的股东总户数，感谢回复。药石科技回复：截至2026年4月20日，公司股东人数42,718名。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400055237.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300725","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629011517","title":"药石科技(300725)3月31日股东户数4.33万户，较上期增加0.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629011517","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629011517?lang=zh_cn&edition=full","pubTime":"2026-04-22 17:32","pubTimestamp":1776850375,"startTime":"0","endTime":"0","summary":"证券之星消息，近日药石科技披露，截至2026年3月31日公司股东户数为4.33万户，较3月20日增加414.0户，增幅为0.97%。在医疗服务行业个股中，药石科技股东户数低于行业平均水平，截至3月31日，医疗服务行业平均股东户数为4.62万户。从股价来看，2026年3月20日至2026年3月31日，药石科技区间涨幅为2.37%，在此期间股东户数增加414.0户，增幅为0.97%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200040924.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300725","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629032294","title":"药石科技(300725.SZ)发布一季度业绩，归母净利润4888.66万元，增长36.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629032294","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629032294?lang=zh_cn&edition=full","pubTime":"2026-04-21 21:31","pubTimestamp":1776778270,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药石科技(300725.SZ)发布2026年第一季度报告，该公司营业收入为5.08亿元，同比增长11.65%。归属于上市公司股东的净利润为4888.66万元，同比增长36.59%。归属于上市公司股东的扣除非经常性损益的净利润为3875.37万元，同比增长26.91%。基本每股收益为0.21元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431566.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药石科技(300725.SZ)发布一季度业绩，归母净利润4888.66万元，增长36.59%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300725"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626255108","title":"药石科技：截至2026年3月31日，公司股东人数43,282名","url":"https://stock-news.laohu8.com/highlight/detail?id=2626255108","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626255108?lang=zh_cn&edition=full","pubTime":"2026-04-12 23:12","pubTimestamp":1776006733,"startTime":"0","endTime":"0","summary":"证券之星消息，药石科技(300725)04月12日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截至2026年3月31日，公司最新股东数是多少？药石科技回复：截至2026年3月31日，公司股东人数43,282名。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041200009754.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","300725"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626082581","title":"药石科技：浙江晖石生产基地多肽GMP中试车间项目目前已完成主体建设","url":"https://stock-news.laohu8.com/highlight/detail?id=2626082581","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626082581?lang=zh_cn&edition=full","pubTime":"2026-04-12 23:12","pubTimestamp":1776006732,"startTime":"0","endTime":"0","summary":"证券之星消息，药石科技(300725)04月12日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司在浙江晖石基地的多肽GMP中试车间预计2026年第一季度投产，可支持从早期研发到GMP生产的全流程转化，满足客户中试及商业化需求…。现在的具体情况进展怎么样了？药石科技回复：投资者您好！浙江晖石生产基地多肽GMP中试车间项目目前已完成主体建设，即将开展设备验证及试运行等相关工作。公司将加快项目建设以更好地满足客户需求。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041200009753.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","300725"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624657429","title":"泓博医药：公司与药石科技未开展相关合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2624657429","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624657429?lang=zh_cn&edition=full","pubTime":"2026-04-03 19:38","pubTimestamp":1775216280,"startTime":"0","endTime":"0","summary":"证券日报网讯4月3日，泓博医药在互动平台回答投资者提问时表示，截至目前，公司与药石科技未开展相关合作。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-04-03/doc-inhtfrev3672977.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-04-03/doc-inhtfrev3672977.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300725","BK0229","BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624635027","title":"诺思格：药石科技为创新药提供临床前服务，我公司为临床CRO公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2624635027","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624635027?lang=zh_cn&edition=full","pubTime":"2026-04-03 08:36","pubTimestamp":1775176572,"startTime":"0","endTime":"0","summary":"证券之星消息，诺思格04月02日在投资者关系平台上答复投资者关心的问题。投资者提问：1.药石科技在分子砌块、连续流工艺、ADC/TPD关键中间体等领域具备国内独一档的技术壁垒，也是很多创新药公司早期研发和CMC开发的重要合作伙伴。药石科技为创新药提供临床前服务，我公司为临床CRO公司，具体业务情况请详见公司定期报告“管理层讨论与分析”章节，两者方向不同。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300009094.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301333","BK0216","06978","159992","BK0229","300725","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624241735","title":"昂利康：目前公司与药石科技暂无合作事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2624241735","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624241735?lang=zh_cn&edition=full","pubTime":"2026-04-02 11:34","pubTimestamp":1775100889,"startTime":"0","endTime":"0","summary":"证券之星消息，昂利康(002940)04月01日在投资者关系平台上答复投资者关心的问题。投资者提问：1. 药石科技在分子砌块、连续流工艺、ADC/TPD关键中间体等领域具备国内独一档的技术壁垒，也是很多创新药公司早期研发和CMC开发的重要合作伙伴。请问贵司在管线研发中，是否与药石科技有合作？未来是否有计划在早期化合物发现、工艺开发或商业化生产层面开展合作？昂利康回复：您好，目前公司与药石科技暂无合作事项，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200015083.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300725","BK0229","002940"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624524964","title":"重药控股：目前公司没有与药石科技合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2624524964","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624524964?lang=zh_cn&edition=full","pubTime":"2026-04-02 11:34","pubTimestamp":1775100881,"startTime":"0","endTime":"0","summary":"证券之星消息，重药控股04月01日在投资者关系平台上答复投资者关心的问题。投资者提问：1.药石科技在分子砌块、连续流工艺、ADC/TPD关键中间体等领域具备国内独一档的技术壁垒，也是很多创新药公司早期研发和CMC开发的重要合作伙伴。未来是否有计划在早期化合物发现、工艺开发或商业化生产层面开展合作？","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200015075.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0071","300725","000950","BK0229","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624595337","title":"4月1日药石科技涨5.63%，方正富邦新兴成长混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2624595337","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624595337?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:17","pubTimestamp":1775031466,"startTime":"0","endTime":"0","summary":"证券之星消息，4月1日药石科技涨5.63%，收盘报38.29元，换手率6.28%，成交量12.74万手，成交额4.8亿元。重仓药石科技的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为方正富邦基金的方正富邦新兴成长混合A。方正富邦新兴成长混合A目前规模为0.65亿元，最新净值1.4139，较上一交易日下跌1.15%，近一年上涨22.97%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100029139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300725","BK0229"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1780532328027,"stockEarnings":[{"period":"1week","weight":-0.0522},{"period":"1month","weight":-0.1343},{"period":"3month","weight":-0.0579},{"period":"6month","weight":-0.0919},{"period":"1year","weight":-0.0262},{"period":"ytd","weight":-0.1053}],"compareEarnings":[{"period":"1week","weight":-0.0024},{"period":"1month","weight":-0.0069},{"period":"3month","weight":-0.006},{"period":"6month","weight":0.0464},{"period":"1year","weight":0.2148},{"period":"ytd","weight":0.029}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"南京药石科技股份有限公司","boardCode":"AI0026","boardName":"化学原料和化学制品制造业","stockholders":"44886人(较上一季度增加5.08%)","perCapita":"4516股","listingDate":"2017-11-10","address":"江苏省南京市浦口区江北新区华盛路81号","registeredCapital":"23380万元","survey":" 南京药石科技股份有限公司的主营业务是为小分子药物研发领域提供创新型化学产品和相关技术服务。公司的主要产品是药物研究阶段的产品和服务、药物开发及商业化阶段的产品和服务。公司在标普全球企业可持续发展评估（S＆PCSA）中得分58分，位列行业前列，入选《可持续发展年鉴（中国版）2026》并荣获“制药行业最佳进步企业”称号；在CDP（全球环境信息研究中心）气候变化与水安全问卷评级中均获得B级。此外，公司再度荣获WindESGAA评级，总分在CRDMO行业中位居前列，其中环境维度获得满分。","listedPrice":11.32},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药石科技(300725)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药石科技(300725)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药石科技,300725,药石科技股票,药石科技股票老虎,药石科技股票老虎国际,药石科技行情,药石科技股票行情,药石科技股价,药石科技股市,药石科技股票价格,药石科技股票交易,药石科技股票购买,药石科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药石科技(300725)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药石科技(300725)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}